Ombipepimut dosing emulsion (ODE) plus bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM)
Samuel Aaron Goldlust,Jong Hee Chang,Yoshitaka Narita,Mary Roberta Welch,Richard M. Green,Jan Drappatz,David Eric Piccioni,Yu Jung Kim, Jason M. Melear,Shota Tanaka,Kuo-Chen Wei, Karen L. Fink,Marshall W. Pitz,Timothy Francis Cloughesy,John Frederick De Groot, Nanci McClellan, Matthew Hitron,Bo Xu, Bo Jin, Claudia Lebedinsky JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
